November 28, 2015
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.



Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Side Effects


Exact incidence figures are not available since no denominator of treated patients is available.

The most serious reaction following prolonged or frequent intermittent use of topical chloramphenicol is bone marrow aplasia.

The most frequently reported adverse reactions have been burning, stinging, ocular irritation, and conjunctival hyperemia. Blood dyscrasias, allergic or inflammatory reactions due to individual hypersensitivity, angioneurotic edema, urticaria, vesicular and maculopapular dermatitis have also been reported (See Warnings and Box Warning).

Read the Chloroptic (chloramphenicol) Side Effects Center for a complete guide to possible side effects


No information provided.

Read the Chloroptic Drug Interactions Center for a complete guide to possible interactions

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 1/2/2005

Side Effects

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.